Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

LeMaitre Vascular, Inc. - Common Stock (NQ:LMAT)

87.56 -0.99 (-1.12%)
Streaming Delayed Price Updated: 9:55 AM EDT, Oct 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about LeMaitre Vascular, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
3 Cash-Producing Stocks We Think Twice About
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak... 
Via StockStory
Where LeMaitre Vascular Stands With Analysts
 
Via Benzinga
3 of Wall Street’s Favorite Stocks We Think Twice About
Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional... 
Via StockStory
Surgical Equipment & Consumables - Specialty Stocks Q2 Earnings Review: LeMaitre (NASDAQ:LMAT) Shines
As the Q2 earnings season wraps, let’s dig into this quarter’s best and worst performers in the surgical equipment & consumables - specialty industry, including LeMaitre (NASDAQ:LMAT) and its peers. 
Via StockStory
Topics Artificial Intelligence Economy
Earnings Scheduled For August 5, 2025
 
Via Benzinga
Earnings Scheduled For May 1, 2025
 
Via Benzinga
1 High-Flying Stock with Solid Fundamentals and 2 We Ignore
Expensive stocks typically earn their valuations through superior growth rates that other companies simply can’t match. The flip side though is that these lofty expectations make them particularly... 
Via StockStory
Healthcare Staffing Giant AMN Healthcare Soars Amidst Landmark Drug-Pricing Agreement
New York, NY – September 30, 2025 – AMN Healthcare Services (NYSE: AMN), a leading provider of healthcare staffing solutions, witnessed a significant upward movement in its stock today, reflecting a... 
Via MarketMinute
Topics Government
Pharmaceutical Stocks Soar as White House Unveils Drug-Pricing Agreement, AbbVie Leads the Charge
Washington D.C. – September 30, 2025 – The pharmaceutical sector experienced a significant upward surge today, notably led by AbbVie (NYSE: ABBV), following reports of a groundbreaking drug-pricing... 
Via MarketMinute
Topics Economy Government World Trade
AbbVie, AMN Healthcare Services, LeMaitre, Waters Corporation, and Organon Shares Skyrocket, What You Need To Know
A number of stocks jumped in the afternoon session after reports revealed a potential drug-pricing agreement between the White House and the pharmaceutical industry. 
Via StockStory
Topics Government
3 Reasons LMAT is Risky and 1 Stock to Buy Instead
Since March 2025, LeMaitre has been in a holding pattern, posting a small return of 1.8% while floating around $85.45. The stock also fell short of the S&P 500’s 18.6% gain during that period. 
Via StockStory
Topics Stocks Supply Chain
Integra LifeSciences and LeMaitre Shares Are Falling, What You Need To Know
A number of stocks fell in the afternoon session after the U.S. Commerce Department initiated a national security investigation into medical equipment and devices, raising concerns about potential... 
Via StockStory
Topics World Trade
1 Profitable Stock with Solid Fundamentals and 2 We Ignore
Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential. 
Via StockStory
LeMaitre Vascular Inc. (NASDAQ:LMAT) Exemplifies Quality Investing Principles in Caviar Cruise Screen
LeMaitre Vascular (LMAT) exemplifies quality investing with strong revenue growth, a 32.83% ROIC, and robust cash flow. A top pick from the Caviar Cruise screen for durable, high-quality stocks. 
Via Chartmill
Astrana Health, Privia Health, Illumina, Waters Corporation, and LeMaitre Shares Plummet, What You Need To Know
A number of stocks fell in the afternoon session after markets pulled back, reversing early gains, as investor sentiment remained cautious despite a softer-than-expected inflation reading. 
Via StockStory
Topics Economy
Why LeMaitre (LMAT) Stock Is Down Today
Shares of medical device company LeMaitre Vascular (NASDAQ:LMAT) fell 2.2% in the afternoon session after the stock traded lower amid broader market weakness. U.S. stock markets began September trading... 
Via StockStory
Topics Bonds Stocks World Trade
LMAT Q2 Deep Dive: International Expansion and Product Momentum Drive Upbeat Outlook
Medical device company LeMaitre Vascular (NASDAQ:LMAT) reported Q2 CY2025 results beating Wall Street’s revenue expectations, with sales up 15% year on year to $64.23 million. Guidance for next... 
Via StockStory
Why LeMaitre (LMAT) Stock Is Trading Up Today
Shares of medical device company LeMaitre Vascular (NASDAQ:LMAT) jumped 9.5% in the afternoon session after the company reported better-than-expected second-quarter financial results and raised its... 
Via StockStory
Topics ETFs Stocks World Trade
LeMaitre (LMAT) Q2 Revenue Jumps 15%
Via The Motley Fool
LeMaitre (NASDAQ:LMAT) Exceeds Q2 Expectations, Full-Year Sales Guidance is Optimistic
Medical device company LeMaitre Vascular (NASDAQ:LMAT) reported revenue ahead of Wall Street’s expectations in Q2 CY2025, with sales up 15% year on year to $64.23 million. Guidance for next quarter’s... 
Via StockStory
LeMaitre (LMAT) Reports Q2: Everything You Need To Know Ahead Of Earnings
Medical device company LeMaitre Vascular (NASDAQ:LMAT) will be reporting results this Tuesday after market close. Here’s what to expect. 
Via StockStory
Topics Artificial Intelligence World Trade
LEMAITRE VASCULAR INC (NASDAQ:LMAT) – A Quality Stock Worth Considering
LEMAITRE VASCULAR INC (NASDAQ:LMAT) shows strong growth, high profitability, and solid financial health, making it a candidate for quality investors. The stock meets key criteria with a 31.7% ROIC and... 
Via Chartmill
Tandem Diabetes, Solventum, LeMaitre, UFP Technologies, and Artivion Stocks Trade Down, What You Need To Know
A number of stocks fell in the afternoon session after the U.S. administration announced a sharp escalation in trade tensions by threatening new tariffs on Canada. The wider market sentiment turned... 
Via StockStory
Topics ETFs Stocks World Trade
Anteris Appoints David Roberts and Gregory Moss to its Board of Directors
New Directors Bring Extensive NASDAQ Expertise Across Legal, Operational and Corporate Leadership Capacities 
From Anteris Technologies Global Corp.
Via GlobeNewswire
Intuitive Surgical (NASDAQ:ISRG): Strongest Q1 Results from the Surgical Equipment & Consumables - Specialty Group
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Intuitive Surgical... 
Via StockStory
Topics Artificial Intelligence Economy
LMAT Q1 Earnings Call: Sales Growth Outpaces Expectations, Margin Pressures Addressed
Medical device company LeMaitre Vascular (NASDAQ:LMAT) beat Wall Street’s revenue expectations in Q1 CY2025, with sales up 12% year on year to $59.87 million. The company expects next quarter’s revenue... 
Via StockStory
Topics World Trade
1 Cash-Heavy Stock That Stand Out and 2 to Question
A cash-heavy balance sheet is often a sign of strength, but not always. Some companies avoid debt because they have weak business models, limited expansion opportunities, or inconsistent cash flow. 
Via StockStory
Q1 Earnings Highs And Lows: LeMaitre (NASDAQ:LMAT) Vs The Rest Of The Surgical Equipment & Consumables - Specialty Stocks
Let’s dig into the relative performance of LeMaitre (NASDAQ:LMAT) and its peers as we unravel the now-completed Q1 surgical equipment & consumables - specialty earnings season. 
Via StockStory
Topics Artificial Intelligence Economy
Why LeMaitre (LMAT) Shares Are Sliding Today
Shares of medical device company LeMaitre Vascular (NASDAQ:LMAT) fell 12.2% in the afternoon session after the company reported weak first quarter 2025 results with a significant miss on full-year EPS... 
Via StockStory
Topics Artificial Intelligence
LeMaitre’s (NASDAQ:LMAT) Q1: Beats On Revenue, Guides for Strong Full-Year Sales
Medical device company LeMaitre Vascular (NASDAQ:LMAT) reported Q1 CY2025 results beating Wall Street’s revenue expectations, with sales up 12% year on year to $59.87 million. Guidance for next... 
Via StockStory
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.